Wave Life Sciences Ltd. (WVE)
WVE Stock Price Chart
Key Info
| Market Cap | 443.88M |
| Revenue (ttm) | 13.04M |
| Net Income (ttm) | -177.89M |
| Shares Out | 38.36M |
| EPS (ttm) | -5.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $9.10 |
| Previous Close | $9.19 |
| Change ($) | -0.09 |
| Change (%) | -0.98% |
| Day's Open | 9.27 |
| Day's Range | 9.00 - 9.50 |
| Day's Volume | 331,506 |
| 52-Week Range | 6.94 - 37.60 |
WVE Stock News
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peopl...
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...
CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...
Investors liked an analyst's upgrade of the biotech stock.
CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.
Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peo...
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Newly created position will focus on translating advancements from PRISM platform into new therapeutic candidates Newly created position will focus on translating advancements from PRISM platf...
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.
Data from both PRECISION-HD clinical trials expected in 2H 2020
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial. The post Wave Life Sciences News: WVE Stock Crashes 50% on Huntington...
Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.
Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals. The post Wh...
WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard. The post Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne...
A lack of efficacy in a lead drug candidate is not what investors were expecting.
No change from baseline in dystrophin observed in Phase 1 open-label extension study
Wave Life Sciences' Suvodirsen May Be Much Better Than Sarepta's Commercialized Eteplirsen, But May Fall Short Of Sarepta's Newer Generation SRP-5051
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.47% and -53.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...
Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping
Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform Wave leadership to present updates on multiple preclinical programs and discuss adva...
New independent directors bring deep expertise in drug development, commercial operations and government affairs New independent directors bring deep expertise in drug development, commercial ...
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peo...
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -16.19% and -51.61%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the st...
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the s...
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About WVE
Wave Life Sciences, a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a re... [Read more...]
| Industry Biotechnology | IPO Date Nov 11, 2015 |
| CEO Paul Bolno | Employees 301 |
| Stock Exchange NASDAQ | Ticker Symbol WVE |
Financial Performance
In 2019, WVE's revenue was $15.98 million, an increase of 10.89% compared to the previous year's $14.41 million. Losses were -$193.64 million, 32.0% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 16.57, which is an increase of 82.09% from the latest price.